Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Wholesalers Settled FY2014 Drug Prices with 70% of Customers at December-End: Official
February 2, 2015
- PAFSC First Committee Backs Approval of Takeda’s Once-Weekly DPP-4 Inhibitor
February 2, 2015
- PM Abe Promises to Introduce Patient-Initiated Mixed-Care System while Maintaining Universal Healthcare
January 30, 2015
- Drug Wholesalers Should Stress Annual Price Cuts “Infeasible”: Ex-Minister
January 30, 2015
- MHLW Warns of Severe Febrile Neutropenia for Cabazitaxel
January 30, 2015
- Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015
January 30, 2015
- Chuikyo’s HTA Panel Holds First Closed-Door Meeting
January 29, 2015
- Expenditure for Senshin-Iryo Services Totaled 17.4 Billion Yen: MHLW
January 29, 2015
- Chuikyo Approves Insurance Reimbursement for Companion Diagnostic for Zelboraf
January 29, 2015
- Government Releases Strategy for Dementia
January 28, 2015
- Prof. Hashida of Kyoto University Elected as PAFSC Chairman
January 28, 2015
- Panel OKs Requirements to Give Legal Status to Clinical Research Core Hospitals
January 27, 2015
- Panel on Unapproved Drugs Weighs Revamp upon Rollout of New Development Request Scheme
January 27, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 12 - 25
January 26, 2015
- Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
- Council OKs Application Based on Info in Public Domain for Taxol Once Weekly for 3 Weeks for Gastric Cancer
January 26, 2015
- PMDA Evaluating Apixaban for Risk of Interstitial Pneumonia
January 26, 2015
- Government Launches Genomic Medicine Panel
January 23, 2015
- Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28
January 23, 2015
- NIBIO Chief Pins Hopes on Potential Synergies from Impending Merger
January 22, 2015
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…